Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus nephritis
Biotech
Nxera sells lupus drug's APAC rights to Viatris for $10M upfront
Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to Viatris for $10 million upfront.
James Waldron
Feb 28, 2025 5:10am
Cabaletta's CAR-T shows 'robust benefit' in autoimmune patients
Feb 19, 2025 11:10am
AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug
Feb 6, 2025 6:45am
GSK aims to extend lupus dominance via $300M T-cell engager deal
Oct 29, 2024 8:00am
FDA places Kezar lupus trial in hold following 4 patient deaths
Oct 7, 2024 5:50am
Kezar suspends key lupus study after 4 deaths
Sep 30, 2024 11:23am
